Current Trials

Trial – AMGEN/IQVIA Suffering from Chronic Hives? A 32-week Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging, Phase 2b Study to Evaluate Efficacy and Safety of xxxxxxxxxx for

Trial – Syneos Health/Eli Lilly Eli Lilly and Company are conducting a Long-term Study to Assess the Safety and Efficacy of xxxxxxxxxxx in Patients With Moderate-to-Severe

Trial – Sun Pharma | IQVIA A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy and Safety of XXXXXXXXX in the Treatment of

Trial -Novartis A multicenter, double-blind, randomized withdrawal extension study of subcutaneous XXXXXXXXXX to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe

Trial -DermTech A Multi-center Sample Collection Study in Patients with a variety of skin conditions including but not limited to Melanoma, Squamous Cell Carcinoma, and

Trial -ICON/Trevi This 1 year study aims to determine the evaluate the safety, tolerability, and effectiveness of nalbuphine as a treatment for the itching related

Trial – Castle Biosciences Prospective Development and Validation of a Gene Expression Assay to Predict the Risk of Recurrence Disease in Cutaneous Squamous Cell Carcinoma

Trial – DermTech A Multi-center Sample Collection Study in Patients with Suspected Melanoma Utilizing DermTech’s Non-invasive Adhesive Patch Biopsy Kits To participate in your local